Assessing OS – the time from treatment to end of life – is considered the most effective means of determining whether a cancer therapy extends life. However, such data often remains incomplete when clinical decisions are needed. Developers instead rely on measures such as progression-free survival and objective response rate. However, these do not always account for the long-term impact of treatment.
The initiative aims to model real-world scenarios such as crossover effects and delayed treatment benefits. MMS was chosen to lead simulation efforts using its KerusCloud platform, which allows realistic modelling of oncology endpoints and exploration of decision thresholds.
“As timely access to innovative cancer therapies remains a key factor for patients, this initiative represents an important step toward optimal acceleration,” said Jeff Allen, president and CEO of Friends of Cancer Research. “We are excited to partner with MMS who bring a combination of statistical depth, real-world understanding of oncology trial design and simulation tools to help tackle these challenges.”
The collaboration is anticipated to help regulators, developers and researchers interpret early survival signals more consistently, supporting faster and more informed decision-making in cancer drug development.
